Results 121 to 130 of about 92,115 (273)

Impact of Metformin and Diabetes on Tumor Response to Total Neoadjuvant Therapy in Advanced Rectal Cancer: A Multicenter Retrospective Cohort Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In advanced rectal cancer patients receiving total neoadjuvant therapy (TNT), overall tumor response did not differ by diabetes status or metformin use. However, among diabetic patients, metformin use was associated with higher overall complete response rates. These findings suggest a potential benefit of metformin in enhancing TNT response in diabetic
Sergei Bedrikovetski, Mahima Raju, Tracy Fitzsimmons, Ishraq Murshed, Timothy J. Price, Michael Penniment, Sudarsha Selva‐Nayagam, Tarik Sammour   +7 more
wiley   +1 more source

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, David Godbolt, Amy Ives, Kirsten Popplewell, Zarnie Lwin, Sally Pearson, Kimberley Nelson, Jason Madore, William C Dougall, Brett G. M. Hughes   +11 more
wiley   +1 more source

Neoadjuvant chemotherapy combined with immunotherapy in selected limited-stage small-cell lung cancer: a retrospective real-world study

Holistic Integrative Oncology
Purpose To clarifythe efficacy and safety of neoadjuvant chemoimmunotherapy—now standard for resectable non-small-cell lung cancer—in patients with limited-stage small-cell lung cancer (LS-SCLC), a setting in which its benefit remains undefined.
Wengang Zhang, Wencheng Zhao, Xuan Chen, Xuyang Chen, Li Ye, Zhimin Chen, Lihua Huang, Kandi Xu, Xinyue Liu, Yayi He   +9 more
doaj   +1 more source

Prognostic Value of Tumor Regression Grade Combined with Pathological Lymph Node Status in Initially Node-Positive Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy

Journal of Investigative Surgery
Background The prognostic value of tumor regression grade (TRG) after neoadjuvant chemoradiotherapy for rectal cancer is inconsistent in the literature.
Dakui Luo, Yajie Chen, Zhouyu Luo, Huangbo Gong, Qingguo Li, Xinxiang Li   +5 more
doaj   +1 more source

Adjuvant Second-Dose Chemotherapy before Surgery for Patients with Locally Advanced Rectal Malignancy Is Not Beneficial: A Systematic Review and Meta-Analysis

Gastroenterology Research and Practice, 2017
Background. Preoperative chemoradiotherapy is the standard treatment for patients with locally advanced rectal cancer, although tumor responses vary widely; some patients may achieve a pathologic complete response rate (pCR) after chemoradiotherapy ...
Min Chen, Xue Song, Liang-zhou Chen, Lin Xu, Yi-pu Lu, Jin-song Zhang   +5 more
doaj   +1 more source

Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
There is limited understanding of the impact of underlying RAS/RAF mutational status on total neoadjuvant therapy metastatic tumor response rates in curative Stage IV rectal cancer patients. Complete metastatic tumor response to TNT was demonstrated in half as many mRAS as wtRAS patients and disease progression was higher in patients harboring RAS ...
Tracy R. Fitzsimmons, Z. Bunjo, E. L. Neo, A. Badiei, M. Penniment, S. Selva‐Nayagam, A. Ruszkiewicz, J. Wong, T. Sammour   +8 more
wiley   +1 more source

Seven Years of Watch and Wait With Rectal Cancer—Reflections and Optimisations

ANZ Journal of Surgery, EarlyView.
ABSTRACT Purpose Sir Charles Gairdner Hospital (SCGH) commenced an observation strategy in patients with a complete clinical response, Watch and Wait (W&W), for rectal adenocarcinoma in 2017 using a rigorous surveillance protocol. Our earlier results (2017–2019) have been published.
Ben Finlay, Emma Powell, Anne Long, Rohen White, John Herron, Michael Warner   +5 more
wiley   +1 more source

Neoadjuvant Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy in Thymic Epithelial Tumors: A Propensity Score-Matched Analysis

Background: Neoadjuvant chemotherapy is generally recommended for locally advanced, potentially resectable thymic epithelial tumors. However, neoadjuvant chemoradiotherapy has been proposed as an alternative approach, potentially achieving higher ...
Taeyoung Yun, Ji Hyeon Park, In Kyu Park, Bubse Na, Hak Jae Kim, Young Tae Kim, Samina Park, Kwon Joong Na, Bhumsuk Keam, Chang Hyun Kang, Hyun Joo Lee   +10 more
core   +1 more source

Anastomotic Failure Is Not Affected by Anastomotic Technique in Minimally Invasive Two‐Stage Oesophagectomy

ANZ Journal of Surgery, EarlyView.
ABSTRACT Background The choice of anastomotic technique in minimally invasive oesophagectomy (MIO) may influence postoperative morbidity and long‐term outcomes. The primary aim of our study is to determine whether circular (CS) or linear‐stapled (LS) anastomosis is associated with anastomotic complications following MIO.
L. Vu, C. Cabalag, L. Ng, B. Choo, A. Hardley, S. Kariyawasam   +5 more
wiley   +1 more source

Kaplan-Meier estimates of relapse-free survival and disease-free survival for patients receiving Neoadjuvant-concurrent chemoradiotherapy versus Concurrent chemoradiotherapy versus IMRT alone.

, 2013
Kaplan-Meier estimates of relapse-free survival and disease-free survival for patients receiving Neoadjuvant-concurrent chemoradiotherapy versus Concurrent chemoradiotherapy versus IMRT alone.
Yajuan Zhou (282972), Xia Fan (282967), Xuemei Ji (282962), Desheng Hu (282965), Conghua Xie (282964), Yingjie Zheng (282977)   +5 more
core   +1 more source